Bionomics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionomics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	35.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Jun 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:B1N0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	1	-37	N/A	N/A	2
6/30/2024	N/A	-15	-15	-15	N/A
3/31/2024	0	-18	-16	-16	N/A
12/31/2023	0	-21	-18	-18	N/A
9/30/2023	0	-20	-15	-15	N/A
6/30/2023	N/A	-21	-15	-15	N/A
3/31/2023	2	-19	-13	-13	N/A
12/31/2022	4	-17	-12	-12	N/A
9/30/2022	4	-15	-13	-13	N/A
6/30/2022	4	-15	-15	-15	N/A
3/31/2022	2	-16	-15	-15	N/A
12/31/2021	0	-16	-14	-14	N/A
9/30/2021	1	-11	-10	-10	N/A
6/30/2021	1	-7	-6	-6	N/A
3/31/2021	1	-3	N/A	N/A	N/A
12/31/2020	1	1	-4	-4	N/A
9/30/2020	2	-2	-3	-3	N/A
6/30/2020	2	-4	-3	-3	N/A
12/31/2019	4	-3	-7	-6	N/A
9/30/2019	5	-5	-8	-8	N/A
6/30/2019	5	-7	-11	-11	N/A
3/31/2019	6	-14	-11	-11	N/A
12/31/2018	5	-20	-11	-10	N/A
9/30/2018	7	-19	-13	-13	N/A
6/30/2018	9	-19	-15	-15	N/A
3/31/2018	15	-12	N/A	-12	N/A
12/31/2017	21	-5	N/A	-8	N/A
9/30/2017	21	-5	N/A	-5	N/A
6/30/2017	21	-5	N/A	-1	N/A
3/31/2017	17	-9	N/A	-5	N/A
12/31/2016	12	-12	N/A	-9	N/A
9/30/2016	14	-13	N/A	-11	N/A
6/30/2016	14	-12	N/A	-11	N/A
3/31/2016	14	-14	N/A	-13	N/A
12/31/2015	13	-15	N/A	-13	N/A
9/30/2015	12	-13	N/A	-5	N/A
6/30/2015	12	-13	N/A	4	N/A
3/31/2015	17	-5	N/A	4	N/A
12/31/2014	24	4	N/A	6	N/A
9/30/2014	25	3	N/A	-3	N/A
6/30/2014	25	3	N/A	-12	N/A
3/31/2014	18	-4	N/A	-9	N/A
12/31/2013	10	-11	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if B1N0's forecast earnings growth is above the savings rate (0.8%).

Earnings vs Market: Insufficient data to determine if B1N0's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if B1N0's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if B1N0's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if B1N0's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if B1N0's Return on Equity is forecast to be high in 3 years time

Bionomics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Bionomics Limited Announces Resignation of Aaron Weaver from the Board of Directors

New minor risk - Financial data availability

Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder

Bionomics Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

New major risk - Shareholder dilution

High number of new and inexperienced directors

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

First half 2024 earnings released: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023

Bionomics Limited, Annual General Meeting, Nov 30, 2023

Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting (Eop2) Meeting with the U.S. Food and Drug Administration

New minor risk - Financial position

Full year 2023 earnings released: AU$3.60 loss per share (vs AU$0.016 loss in FY 2022)

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies